ALMS

Alumis Inc. operates as a clinical-stage biopharmaceutical company focused on developing oral therapies for autoimmune and inflammatory diseases. Headquartered in South San Francisco, California, the company was founded in 2020 and concentrates on creating precision medicines that target specific immune cell subsets to treat diseases with significant unmet medical needs. Alumis's lead product candidate, ESK-001, is an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor in development for moderate-to-severe plaque psoriasis and systemic lupus erythematosus. The company's pipeline also includes A-005, an oral TREX1-mutant selective STING inhibitor targeting STING-associated vasculopathy with onset in infancy (SAVI), and additional programs addressing other autoimmune conditions. Alumis completed its initial public offering in May 2024, raising approximately $259 million to advance its clinical programs. The company holds exclusive worldwide rights to develop and commercialize ESK-001 through a licensing agreement with Eli Lilly and Company. Alumis employs a targeted approach to drug development, utilizing biomarker-driven patient selection to identify populations most likely to benefit from its therapies. The company maintains strategic collaborations and continues to expand its pipeline through both internal research and in-licensing opportunities, positioning itself within the competitive autoimmune therapeutics market.